Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CFD | P00746 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 10/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29231252 | 1.00 | HTRA1 (0.43) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29231256 | 1.00 | HTRA1 (0.43) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29231253 | 1.00 | HTRA1 (0.43) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29230959 | 0.89 | CFD (0.38) | CFDITGA4 | |
| SCHEMBL29230963 | 0.89 | CFD (0.38) | CFDITGA4 | |
| SCHEMBL29230956 | 0.89 | CFD (0.38) | CFDITGA4 | |
| SCHEMBL24665819 | 0.87 | HTRA1 (0.45) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL24664650 | 0.84 | HTRA1 (0.44) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29231608 | 0.84 | HTRA1 (0.44) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29231612 | 0.84 | HTRA1 (0.44) | HTRA1CYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-07-25 | — | — | US | disclosed |
| CN-117956985-A | Inhibitors of glycogen synthase 1 (GYS 1) and methods of use thereof | 梅兹治疗公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4308095-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | HTRA1 4038/4885CYP1A2 878/4885POLB 2862/4885 |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | HTRA1 4038/4885CYP1A2 878/4885POLB 2862/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | HTRA1 4782/4885CYP1A2 2531/4885POLB 1627/4885 |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | HTRA1 4038/4885CYP1A2 878/4885POLB 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.